Processes for manufacturing compositions comprising lifitegrast and semifluorinated alkanes

A process for manufacturing a stable, preservative-free suspension of lifitegrast in semifluorinated alkane addresses the need for improved dry eye disease treatment by ensuring consistent delivery and reducing ocular irritation, achieving high stability and potency without additional excipients.

WO2026234036A1PCT designated stage Publication Date: 2026-11-12BAUSCH & LOMB IRELAND LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062994
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-27
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for improved ophthalmic compositions for treating dry eye disease that are stable, sterile, and free or substantially free of potentially irritating antioxidants and/or preservatives, with the ability to provide consistent delivery of lifitegrast to the eye without causing grittiness or requiring additional excipients.

Method used

A process for manufacturing a suspension comprising lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane, such as perfluorohexyloctane, which involves sterilizing both components separately and mixing them to form a stable suspension, optionally followed by ball milling to reduce particle diameter, resulting in a preservative-free and antioxidant-free composition.

Benefits of technology

The resulting suspension achieves high stability and potency, allowing for consistent delivery of lifitegrast to the eye, reducing the need for additional excipients and minimizing ocular irritation, while maintaining efficacy with a reduced dose.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062994_12112026_PF_FP_ABST
    Figure EP2026062994_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A process for manufacturing an ophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, wherein the process comprises: (i) providing, separately, (a) sterilized lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilized semifluorinated alkane; and (ii) mixing the sterilized lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilized semifluorinated alkane, thereby forming a suspension.
Need to check novelty before this filing date? Find Prior Art

Description

PROCESSES FOR MANUFACTURING COMPOSITIONS COMPRISING LIFITEGRAST AND SEMIFLUORINATED ALKANES

[0001] This application claims the benefit of United States Patent Application 63 / 800,766, filed May 6th 2025, and European Patent Application 25178996.2, filed 27th May 2025, the complete contents of which are incorporated herein by reference.

[0002] The invention relates to a process for manufacturing an ophthalmic composition in the form of a suspension comprising (a) I ifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane.BACKGROUND

[0003] Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a multifunctional disorder of the tear film, and ocular surface which results in discomfort, visual disturbance, and often even in ocular surface damage. Secondary diseases whose development may be triggered by dry eye disease include filamentary keratitis, microbial keratitis, corneal neovascularisation, and ocular surface keratinisation. Two major categories of dry eye disease are distinguished today, which are aqueous-deficient DED and evaporative DED. These conditions are not necessarily mutually exclusive.

[0004] Within the class of aqueous-deficient forms of dry-eye disease, two major subtypes are differentiated, Sjogren and non-Sjdgren. Evaporative DED is associated with increased evaporative loss of the tear film and can develop as a result of diverse root causes including meibomian gland disease, eyelid aperture disorders, blink disorders (as in Parkinson disease) or ocular surface disorders (as in allergic conjunctivitis).

[0005] Typically, ophthalmic compositions for treatment of dry eye disease are administered as eye drops, with one or more drops of the composition being applied to an eye of the subject suffering from or susceptible to the disease one or more times per day, although the frequency of administration of such compositions may be dependent on multiple factors, including the makeup of the particular composition.

[0006] Lifitegrast (the active ingredient of Xiidra®) is a small molecule lymphocyte function-associated antigen 1 (LFA-1) antagonist that has been approved for the treatment of signs and symptoms of dry eye disease. It has the following structure:

[0007] Despite the success of Xiidra in meeting the needs of many patients suffering from dry eye disease, there remains a need for improved dry eye disease treatments, particularly those that are stable, sterile, and having lesser concentrations of or even substantially free of potentially irritating antioxidants and / or preservatives.

[0008] Disclosed herein and in PCT / EP2024 / 082568 are improved, stable ophthalmic compositions comprising (a) lifitegrast; and (b) at least one semifluorinated alkane. These compositions may be preservative-free and / or free of antioxidants. Without wishing to be bound by theory, it is believed that, not only does the at least one semifluorinated alkane provide its own ocular disorder treatment and / or prevention effect (thus intersecting the disease cycle with effects on both inflammation and tear evaporation), but it also acts as a stable, non-aqueous vehicle or carrier for the lifitegrast. The non-aqueous nature also allows for the reduction or elimination of the need for additional ingredients, such as antioxidants and / or preservatives. This circumvents the potential for ocular damage from preservatives, which is particularly high among patients suffering from chronic diseases, such as dry eye disease, that require daily eye drop instillations for periods of years to decades. Moreover, the ability to prepare a product which does not need an extrinsic preservative means that it can be provided in a multi-dose format, which reduces the waste and cost associated with packaging materials. The unique combination of the lifitegrast and the at least one semifluorinated alkane thus provides improved, stable ophthalmic compositions. Furthermore, the compositions can achieve similar ocular exposure as aqueous lifitegrast compositions but with only one third of the dose.

[0009] There is a need for processes for manufacturing these novel ophthalmic compositions, which are in the form of a suspension of lifitegrast particles in the semifluorinated alkane. The final suspensions should be suitable for delivery to the eye, for example, the suspension should be sterile and not cause a sensation of grittiness in the eye. Ideally, the final suspensions should allow consistent delivery of lifitegrast to the eye, for example, by being readily dispersible or by forming a stable suspension (i.e., where there is no appreciable settling observed over a prolonged period).SUMMARY OF THE INVENTION

[0010] The present inventors have found that sterile, stable ophthalmic compositions in the form of a suspension comprising (a) I ifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane may be manufactured by a process comprising (i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension. Preferably, the process is a process for manufacturing a composition consisting of sterilised lifitegrast and at least one sterilised semifluorinated alkane. The at least one sterilised semifluorinated alkane preferably consists of sterilised F6H8. Therefore, the ophthalmic composition formed by the process may be in the form of a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane. The process preferably comprises: (i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the sterilised perfluorohexyloctane, thereby forming a suspension. Preferably, said suspension consists of sterilised lifitegrast and sterilised F6H8.

[0011] This and other features, aspects, and advantages of the disclosure will be apparent from a reading of the following.Definitions

[0012] Definitions of certain terms as used in this application are provided below. Unless defined otherwise, all technical and scientific terms used herein have the normal and common meaning that would be commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0013] As used herein, the term “about” means approximately, in the region of, roughly, or around. The term “about” in relation to a numerical value x is optional and means, for example, x ± 5%. Numerical values disclosed with the term “about” include the specifically identified value. For example, “about 100” means a number ranging from 95 to 105, including 95, 100, and 105.

[0014] As used herein, “administration” of a compound or composition to a patient refers to any route of introducing or delivering the compound or composition to a subject. Administration includes self-administration and the administration by another.

[0015] As used herein, a “condition,” “disorder,” or “disease” refers to any unhealthy or abnormal state.

[0016] As used herein, an “effective amount” or “effective dose” refers to an amount of a compound or composition that treats and / or temporarily prevents, upon single or multiple dose administration, a patient suffering from a disorder, disease, or condition. An effective amount can be determined by the attending diagnostician through the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of patient; its size, age, and general health; the specific condition, disorder, or disease involved; the degree of or involvement or the seventy of the condition, disorder, or disease, the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

[0017] As used herein, a composition is “free” of a component when it comprises no detectable amount of the component.

[0018] As used herein, the term “consists essentially of” means that, in addition to the mandatory ingredients, specific further ingredients can be present, namely those not materially affecting the essential characteristics of the composition or component in question. For example, a composition consisting essentially of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane may contain lifitegrast or a pharmaceutically acceptable salt thereof, impurities derived from lifitegrast that are generated during the process of sterilising the lifitegrast or a pharmaceutically acceptable salt thereof, and the at least one semifluorinated alkane. Compositions or components herein which “consist essentially of” the specified ingredients may consist only of the specified ingredients, with no other ingredients present (in which case the composition “consists of” the specified ingredients).

[0019] As used herein, the terms “patient,” “subject,” “individual,” and the like, as used herein, are interchangeable and refer to any animal, which may be a human or a nonhuman animal. Compositions of the invention are particularly suited to use in humans and so the patient is preferably a human.

[0020] As used herein, the terms “prevention” of or “preventing” a disorder, disease, or condition refers to reducing the severity and / or the occurrence of the disorder, disease, or condition in a treated sample relative to an untreated control sample, and includes delaying onset and / or progression of the disorder or condition relative to the untreated control sample.

[0021] As used herein, the term “ocular disorder” refers to any of the signs, symptoms, and / or underlying cause(s) of any physiological disorder that affects the eye or vision.

[0022] As used herein, the term “particle diameter” refers to the equivalent spherical diameter (esd), i.e., the diameter of a sphere having the same volume as a given particle. The terms “Dn” and “Dnparticle diameter” refer to the diameter below which n% by volume of the particle population is found. Thus, the terms “Dso” and “Dso particle diameter” refer to the volume-based median particle diameter below which 50% by volume of the particle population is found, and the terms “D90” and “D90 particle diameter” refer to the particle diameter below which 90% by volume of the particle population is found. Particle diameters can be determined by laser diffraction, for example in accordance with U.S. Pharmacopeia chapter <429>, 2024. The particle diameter of I ifitegrast or a pharmaceutically acceptable salt thereof, such as the D90 or D50 particle diameter, in at least one semifluorinated alkane may be determined using routine laser diffraction methods. In particular, the particle diameter may be determined using a light diffraction particle analyser (e.g., Horiba LA-960) preferably equipped with a circulation system (e.g., Horiba MiniFlow), for example using the LA-960 for Windows V8.40 software. The particle size may be determined using Mie theory, for example using a real and imaginary refractive index of 1.643 and 0.1 respectively. Preferably, a dispersant, such as 0.1% (w / w) sorbitan monooleate (e.g. Span® 80) in heptane, may be added to improve the separation of the lifitegrast particles. Optionally, the mixture of lifitegrast suspension and dispersant consists of about 1% (w / w) suspension and about 99% (w / w) dispersant.

[0023] As used herein, a “pharmaceutically acceptable excipient” refers to a carrier or an excipient that is useful in preparing a pharmaceutical composition. For example, a pharmaceutically acceptable excipient is generally safe and includes carriers and excipients that are generally considered acceptable for mammalian pharmaceutical use. As a non-limiting example, pharmaceutically acceptable excipients may be solid, semi-solid, or liquid materials which, in the aggregate, can serve as a vehicle or medium for active ingredients. Some examples of pharmaceutically acceptable excipients are found in Remington’s Pharmaceutical Sciences and Rowe’s Handbook of Pharmaceutical Excipients and include diluents, vehicles, carriers, ointment bases, binders, stabilizing agents, preservatives, solvents, suspending agents, and others. In the ophthalmic compositions of the present disclosure, the at least one semifluorinated alkane is not a “pharmaceutically acceptable excipient” because it provides its own ocular disorder treatment and / or prevention effect.

[0024] As used herein, a container closure system is the sum of packaging components that collectively contain the ophthalmic composition. For example, the container closure system may consist of a bottle, a droplet-forming outlet, and a screw cap. Alternatively, the container closure system may consist of a vial, which is integrally formed with a droplet forming outlet, and a cap that forms an interference fit with the droplet forming outlet.

[0025] As used herein, a bottle is a container for storing and dispensing a liquid ophthalmic composition having a neck, a body that is wider than the neck, and a base that allows the bottle to stand upright on a flat surface. The body of the bottle is squeezable by hand to dispense the composition through the neck.

[0026] As used herein, a vial is a container for storing and dispensing a liquid ophthalmic composition. It is squeezable by hand to dispense the composition through an outlet. The vial typically is or forms part of a multi-dose container closure system. The vial may comprise a tapered section that is snapped open to form the dropletforming outlet. The vial may comprise a neck at one end, with a circular cross section, and may be crimped at the other end to form a seal, giving an elliptical cross-section through the body of the vial. Unlike a bottle, a vial typically lacks a base that allows it to stand upright on a flat surface.

[0027] As used herein, a “pharmaceutically acceptable salt” is a salt that is suitable for use in contact with tissues of humans without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, N+H3(Ci-4alkyl) and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Examples of pharmaceutically acceptable acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0028] As used herein, a composition is “stable” if the lifitegrast within the composition degrades by less than about 10% (i.e., at least 90% of the lifitegrast is intact) after being stored at about 25 °C for 10 weeks, as measured by high-performance liquid chromatography (HPLC) or an equivalent appropriate technique such as that within the U.S. Pharmacopeia, preferably by HPLC.

[0029] As used herein, a composition is “sterile” if it has a microbial bioburden of less than or equal to 0.1 CFU / ml, as measured by a standard plate count method or an equivalent appropriate technique such as that within the U.S. Pharmacopeia.

[0030] As used herein, a substance, composition, or container closure system is “sterilised” if the substance, composition, or container closure system has been subjected to a sterilisation process, such as sterilisation by ethylene oxide or gamma irradiation.

[0031] As used herein, the term “treat,” “treating,” or “treatment,” when used in connection with a disorder or condition, includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the disorder or condition. Improvements in or lessening the seventy of any symptom of the disorder or condition can be readily assessed according to standard methods and techniques known in the art.

[0032] As will be understood by one of ordinary skill in the art, each range disclosed herein includes all possible subranges as well as individual numerical values within that range, including endpoints. As a non-limiting example, a range of “0.001% to 0.02%” includes the endpoints of 0.001% and 0.02%, and would be understood to specifically disclose subranges such as “0.004% to 0.01%,” “0.005% to 0.02%,” etc., as well as all individual numbers within the disclosed range, for example, 0.001%, 0.004%, 0.005%, 0.01%, 0.02%, etc.

[0033] Any percentage concentration values disclosed herein are on a weight-per-weight (w / w) basis unless otherwise specified.

[0034] Unless specifically stated, a process or method comprising a step of mixing two or more components does not require any specific order of mixing. Thus, components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.

[0035] The various steps of the methods or processes herein may be carried out at the same time or at different times, in the same or different geographical locations, e.g., countries, and by the same or different people or entities.DETAILED DESCRIPTION OF THE INVENTION

[0036] The process of the present disclosure for manufacturing an ophthalmic composition in the form of a suspension comprising (a) I if itegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane comprises: (i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension. Preferably, the process of the invention is for manufacturing a composition consisting of (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane (F6H8). Therefore, the process preferably comprises: (i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the sterilised perfluorohexyloctane, thereby forming a suspension. Said suspension preferably consists of (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane (F6H8).

[0037] The process may comprise:(i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane;(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension;(iii) ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof.

[0038] The process may comprise:(i) providing, separately, (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane;(ii) sterilising the lifitegrast or a pharmaceutically acceptable salt thereof;(iii) sterilising the at least one semifluorinated alkane;(iv) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension;(v) ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof;(vi) adding a second portion of the at least one sterilised semifluorinated alkane to the suspension after the suspension has been subjected to ball milling.

[0039] The process may comprise:(i) providing, separately, (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane;(ii) sterilising the lifitegrast or a pharmaceutically acceptable salt thereof;(iii) sterilising the perfluorohexyloctane;(iv) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the perfluorohexyloctane, thereby forming a suspension;(v) ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and perfluorohexyloctane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof;(vi) adding a second portion of perfluorohexyloctane to the suspension after the suspension has been subjected to ball milling.

[0040] The process may further comprise:(vii) filling the suspension into a container closure system.Suspension of lifitegrast in semifluorinated alkane formed by the process

[0041] The process can be used to form a suspension comprising from about 0.5% (w / w) to about 10% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, for example from about 2% (w / w) to about 6% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis. Preferably, the final suspension produced by the process comprises about 2.5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, or the suspensioncomprises about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis.

[0042] The process can be used to form a suspension comprising from about 90% (w / w) to about 99.5% (w / w) of the at least one sterilised semifluorinated alkane, for example from about 94% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane. Preferably, the final suspension produced by the process comprises about 95% (w / w) of the at least one sterilised semifluorinated alkane, or the suspension comprises about 97.5% (w / w) of the at least one sterilised semifluorinated alkane.

[0043] As explained further herein, it has surprisingly been found that suspensions containing lifitegrast and a semifluorinated alkane exhibit excellent stability and high potency without the addition of any preservative, antioxidant, or any other excipients. Therefore, preferably, the process can be used to form a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane; for example a suspension consisting essentially of (a) from about 2.5% (w / w) to about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) from about 95% (w / w) to about 97.5% (w / w) of the at least one sterilised semifluorinated alkane. Advantageously, this suspension may be free of any preservative and free of any antioxidant. The process may be used to form a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane, for example a suspension consisting of (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane. Preferably, the process is used to form a suspension that consists of (a) from about 2.5% (w / w) to about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) from about 95% (w / w) to about 97.5% (w / w) of the at least one sterilised semifluorinated alkane. More preferably, the process is used to form a suspension that consists of (a) from about 2.5% (w / w) to about 5% (w / w) of sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis, and (b) from about 95% (w / w) to about 97.5% (w / w) of sterilised perfluorohexyloctane.

[0044] The combined weight of the (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and the (b) sterilised at least one semifluorinated alkane may be more than 99.5% (w / w) of the total weight of the ophthalmic composition.(a) Lifitegrast

[0045] The process uses sterilised lifitegrast or a pharmaceutically acceptable salt thereof. The lifitegrast that is used in the process may be in the form of apharmaceutically acceptable salt, but most preferably is in the form of lifitegrast free acid. When lifitegrast is used in the form of a pharmaceutically acceptable salt, the pharmaceutically acceptable salt is preferably selected from sodium, potassium, arginine, and tris(hydroxymethyl)aminomethane salts, more preferably a sodium salt. Where a salt is used, concentrations or amounts of lifitegrast disclosed herein are calculated according to the corresponding quantity of lifitegrast free acid, i.e. , on a free acid basis.

[0046] The process can be used to form a suspension comprising lifitegrast or a pharmaceutically acceptable salt thereof at a concentration from about 0.1% (w / w) to about 10% (w / w), for example, from about 1% (w / w) to about 10% (w / w), from about 2% (w / w) to about 10% (w / w), from about 2% (w / w) to about 8% (w / w), from about 2% (w / w) to about 6% (w / w), or from about 2.5% (w / w) to about 5% (w / w) on a free acid basis. Preferably, the concentration of lifitegrast or a pharmaceutically acceptable salt thereof is about 2.5% (w / w) or about 5% (w / w) on a free acid basis.(b) Semifluorinated alkanes

[0047] The process uses at least one sterilised semifluorinated alkane. Semifluorinated alkanes are linear or branched alkanes with fluorine atoms in place of some of the hydrogen atoms of the corresponding non-fluorinated alkane. In particular, semifluorinated alkanes are compounds composed of at least one perfluorinated hydrocarbon segment and at least one non-fluorinated hydrocarbon segment. According to a nomenclature used herein, the semifluorinated alkanes may be referred to as FnHm, wherein F refers to the perfluorinated hydrocarbon segment (F-segment), H refers to the non-fluorinated hydrocarbon segment (H-segment), and n and m refer to the number of carbon atoms of those segments, respectively. For example, F6H8 is used to refer to perfluorohexyloctane.

[0048] This type of nomenclature is typically used for compounds wherein the perfluorinated carbons are bonded together to form a single linear F-segment and the non-fluorinated carbons are bonded together to form a single linear H-segment. Typically, the perfluorinated F-segment is attached to an end of the non-fluorinated H-segment, i.e., it is attached to C1, so that the overall molecule is linear. However, a minority of branched compounds, wherein two linear (F and H) segments are joined at a different position such as C2, may be present. In the case of perfluorohexyloctane (F6H8), the perfluorohexyloctane comprises 95% (w / w) or more of 1 -perfluorohexyloctane, preferably 98% (w / w) or more, more preferably 99.5% (w / w) or more. Preferably, the balance is 2-perfluorohexyloctane.

[0049] The process can be used to form a suspension comprising at least one semifluorinated alkane at a concentration of at least about 90% (w / w), for example, at least about 95% (w / w). The concentration of at least one semifluorinated alkane may be from about 90% (w / w) to about 99.5% (w / w), for example, from about 94% (w / w) to about 98% (w / w).

[0050] The at least one semifluorinated alkane used in the process may be chosen from F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may be chosen from F4H4, F4H5, F4H6, F5H5, F5H6, F5H7, F5H8, F6H6, F6H7, F6H8, F6H9, F6H10, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may be chosen from F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, or any combination thereof. Preferably, the process uses no more than two semifluorinated alkanes.

[0051] Preferably, the at least one semifluorinated alkane comprises at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10). The at least one semifluorinated alkane may consist essentially of at least one of perfluorohexyloctane (F6H8) and perfluorohexyldecane (F6H10).

[0052] More preferably, the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8). Most preferably, the semifluorinated alkane used in the process is F6H8 and is substantially free of other semifluorinated alkanes besides F6H8. As used herein, “substantially free of other semifluorinated alkanes” means that other semifluorinated alkanes are present at a relative amount of 2% (w / w) or less, preferably 1% (w / w) or less, or more preferably 0.5% (w / w) or less based on the total amount of semifluorinated alkanes in the composition. F6H8 may be the only semifluorinated alkane used in the process and present in the suspension formed by the process.(c) Other components

[0053] Preferably, the process does not comprise adding water or any pharmaceutically acceptable excipients. Thus, process can be used to form a suspension that preferably does not comprise water or any pharmaceutically acceptable excipients.

[0054] Preferably, the process can be used to form a suspension that is substantially free of pharmaceutically acceptable excipients. As used herein, a composition may be “substantially free of pharmaceutically acceptable excipients” when excipients arepresent at an amount of 0.5% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The suspension may be free of pharmaceutically acceptable excipients.

[0055] Preferably, the process does not comprise adding a medium chain triglyceride. Thus, the ophthalmic composition formed by the process may be substantially free of medium chain triglycerides. Medium-chain triglycerides are triglycerides of fatty acids. The fatty acids have an aliphatic chain of 6-12 carbon atoms, and can be, for example, hexanoic acid, octanoic acid, decanoic acid, and dodecanoic acid. Therefore, a medium chain triglyceride may be a triglyceride of fatty acids, wherein the fatty acids comprise hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid or combinations of two or more thereof. As used herein, a composition may be “substantially free of medium chain triglycerides” when medium chain triglycerides are present at an amount of 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of medium chain triglycerides.

[0056] Medium-chain triglycerides include coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin. Accordingly, the ophthalmic composition may be substantially free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin. As used herein, a composition may be “substantially free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin” when the combined amount of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin present in the composition is 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of coco-caprylate / caprate, propylene glycol dicaprylocaprate, glyceryl tricaprylate / tricaprate, and glyceryl tricaprylate / tricaprylin.

[0057] Preferably, the process does not comprise adding a semifluorinated alkyl alcohol. The ophthalmic composition may be substantially free of semifluorinated alkyl alcohols. As used herein, a composition may be “substantially free of semifluorinated alkyl alcohols” when semifluorinated alkyl alcohols are present at an amount of 0.4% (w / w) or less, preferably 0.1% (w / w) or less, or more preferably 0.05% (w / w) or less, based on the total weight of the composition. The ophthalmic composition may be free of semifluorinated alkyl alcohols.

[0058] Preferably, the process does not comprise adding a medium chain triglyceride and does not comprise adding a semifluorinated alkyl alcohol. Accordingly, the ophthalmic composition is substantially free of medium chain triglycerides and substantially free of semifluorinated alkyl alcohols. Preferably, the ophthalmic composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.

[0059] Preferably, the process does not comprise adding a preservative or antioxidant.

[0060] The process may comprise adding one or more antioxidants to prevent oxidative degradation of the lifitegrast. The one or more antioxidants may comprise a thiosulfate salt, such as sodium thiosulfate. The antioxidants may comprise a metabisulfite salt, such as sodium bisulfate.

[0061] Other antioxidants which can be used to form pharmaceutical formulations include, but are not limited to, propyl, octyl and dodecyl esters of gallic acid, butylated hydroxyanisole (BHA, usually purchased as a mixture of ortho and meta isomers), green tea extract, uric acid, cysteine, pyruvate, nordihydroguaiaretic acid, ascorbic acid, salts of ascorbic acid such as ascorbyl palmitate and sodium ascorbate, ascorbyl glucosamine, vitamin E (i.e., tocopherols such as a-tocopherol), derivatives of vitamin E (e.g., tocopheryl acetate), retinoids such as retinoic acid, retinol, trans-retinol, cisretinol, mixtures of trans-retinol and cis-retinol, 3-dehydroretinol and derivatives of vitamin A (e.g., retinyl acetate, retinal and retinyl palmitate, also known as tetinyl palmitate), sodium citrate, sodium sulfite, lycopene, anthocyanids, bioflavinoids (e.g., hesperitin, naringen, rutin and quercetin), superoxide dismutase, glutathione peroxidase, butylated hydroxytoluene (BHT), indole-3-carbinol, pycnogenol, melatonin, sulforaphane, pregnenolone, lipoic acid and 4-hydroxy-5-methyl-3[2H]-furanone. The process disclosed herein can be used to form a suspension wherein one or more, or all, of the above antioxidants is excluded, or is present in less than effective amounts, either alone or in combination.

[0062] The amount of antioxidants present in the suspension formed by the process may be in the range of about 0.01 - about 0.5% w / v. The amount of antioxidants present may be in the range of about 0.1 -about 0.5%, about 0.2-about 0.5%, about 0.3-about 0.5%, about 0.4-about 0.5%, about 0.01 -about 0.4%, about 0.1 -about 0.4%, about 0.2-about 0.4%, about 0.3-about 0.4%, about 0.01 -about 0.3%, about 0.1 -about 0.3%, about 0.2-about 0.3%, about 0.01 -about 0.2%, about 0.1 -about 0.2%, or about 0.01-about 0.1% w / v. Sodium thiosulfate may be present in an amount to provide antioxidant stability to the formulation, and the amount of sodium thiosulfate as a percentage by weight of all total antioxidants may be greater than 50% by weight.

[0063] Vitamin E and / or derivatives of vitamin E may be present in an amount to provide antioxidant stability to the formulation, and the amount of vitamin E and / or derivatives of vitamin E as a percentage by weight of all total antioxidants may be greater than 50% by weight.

[0064] It is also possible, and preferred, for the process to not involve adding any antioxidants, thus simplifying its preparation and avoiding potential irritation caused by antioxidant chemicals. The ability to maintain lifitegrast in stable form despite the absence of antioxidant is particularly surprising because oxygen is highly soluble in semifluorinated alkanes (and in particular in F6H8). The Xiidra product includes sodium thiosulfate as an antioxidant.

[0065] The process can comprise adding a preservative. The preservative may be selected from benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro complex, polyquaternium-1 , chlorobutanol, edetate disodium, polyhexamethylene biguanide, a composition containing boric acid, sorbitol, propylene glycol, and zinc chloride (e.g., SofZia®), or combinations thereof.

[0066] The amount of preservatives present in a suspension formed by the process may be in the range of about 0.01 -0.5% w / v. The amount of preservatives present may be in the range of about 0.1 -about 0.5%, about 0.2-about 0.5%, about 0.3-about 0.5%, about 0.4-about 0.5%, about 0.01 -about 0.4%, about 0.1 -about 0.4%, about 0.2-about 0.4%, about 0.3-about 0.4%, about 0.01 -about 0.3%, about 0.1 -about 0.3%, about 0.2-about 0.3%, about 0.01 -about 0.2%, about 0.1 -about 0.2%, or about 0.01 -about 0.1% w / v.

[0067] It is also possible, and preferred, for the process to involve not adding any preservative, i.e. , to form a suspension that is free from preservatives even when it is filled into a multi-dose container. This simplifies the preparation of the suspension and avoids potential irritation caused by known preservatives. Without wishing to be bound by theory, it is believed that the semifluorinated alkane can provide a preservative effect, as well as providing a therapeutic ocular effect.

[0068] Thus, preferably, the process does not involve adding any anti oxidants and / or does not involve adding any preservatives, i.e., it forms a suspension that is substantially free of anti oxidants and / or substantially free of preservatives (save for semifluorinated alkanes, considering these as preservatives). Preferably, the process forms a suspension that is substantially free of the antioxidants listed above and / or substantially free of the preservatives listed above. Further preferably, the process forms a suspension that is substantially free of both antioxidants and preservatives. As used herein, a composition may be “substantially free of antioxidants” whenantioxidants are present at an amount of 0.1% (w / w) or less, preferably 0.05% (w / w) or less, or more preferably 0.01% (w / w) or less, based on the total weight of the composition. As used herein, a composition may be “substantially free of preservatives” when preservatives (save for semifluorinated alkanes, considering these as preservatives) are present at an amount of 0.1% (w / w) or less, preferably 0.05% (w / w) or less, or more preferably 0.01 % (w / w) or less, based on the total weight of the composition. The suspension may be free of the antioxidants listed above and / or free of the preservatives listed above. Further preferably, the process forms a suspension that is free of both antioxidants and preservatives.

[0069] Preferably the process can be used to form a suspension that is substantially free of water. As used herein, a composition may be “substantially free of water” when the suspension comprises water at an amount of 1% (w / w) or less, preferably 0.5% (w / w) or less, or more preferably 0.1% (w / w) or less, based on the total weight of the composition. The suspension formed by the process may be free of water.Sterilisation

[0070] The process may comprise sterilising the lifitegrast or a pharmaceutically acceptable salt thereof. It will be understood by a person skilled in the art that sterilising a substance, such as lifitegrast, does not involve subjecting it to a process that causes high levels of degradation, since this would adversely affect its activity. Thus, preferably, the amount of lifitegrast or a pharmaceutically acceptable salt thereof after sterilisation is about 97 mol% or more of the amount of lifitegrast or a pharmaceutically acceptable salt thereof before sterilisation, more preferably about 98 mol% or more of the amount of lifitegrast or a pharmaceutically acceptable salt thereof before sterilisation.

[0071] The lifitegrast or a pharmaceutically acceptable salt thereof may be sterilised by sterile filtration (e.g., in the form of a solution), gamma irradiation, or ethylene oxide. The lifitegrast or a pharmaceutically acceptable salt thereof may be sterilised by gamma irradiation, preferably wherein the radiation dose is from about 15 kGy to about 40 kGy. This radiation dose range has been found to sterilise lifitegrast effectively without generating an unacceptable level of impurities. The sterilisation of lifitegrast or a pharmaceutically acceptable salt thereof contributes to ensuring that the final suspension is free of micro-organisms that might cause infections in the eye after administration.

[0072] The process may comprise sterilising the at least one semifluorinated alkane. The at least one semifluorinated alkane may be sterilised by sterile filtration, dry heat sterilisation, gamma irradiation, or gas sterilisation (e.g. using ethylene oxide).Preferably, the at least one semifluorinated alkane is sterilised by sterile filtration. As for lifitegrast, the sterilisation of the at least one semifluorinated alkane contributes to ensuring that the final suspension is free of micro-organisms that might cause infections in the eye after administration.

[0073] When the at least one semifluorinated alkane is sterilised by sterile filtration, the sterile filter may be selected from a 0.1 micron filter, 0.2 micron filter, and 0.22 micron filter. Preferably, the sterile filter is a 0.2 micron filter. A person skilled in the art would understand that “X micron filter” refers to a filter that will remove particles larger than X microns. The filter material may be selected from nylon, polycarbonate, cellulose acetate, polyvinylidene (PVDF), and polyethersulfone (PES), preferably from polyvinylidene (PVDF) and polyethersulfone (PES). A sterile filter should remove 107bacteria (usually B. diminuta) per cm2of effective filtration area, as tested by a standard test method such as ASTM F838-20.

[0074] To preserve the sterility of the lifitegrast or a pharmaceutically acceptable salt thereof and the at least one semifluorinated alkane, the subsequent steps of the process should be conducted aseptically.

[0075] Although less preferred than sterilising the lifitegrast or a pharmaceutically acceptable salt thereof and the at least one semifluorinated alkane separately prior to mixing, the process may instead comprise mixing lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane to form a suspension, and then sterilising the suspension, for example using gamma irradiation. In such instances, the lifitegrast or a pharmaceutically acceptable salt thereof has not been subjected to a sterilisation process prior to mixing with the at least one semifluorinated alkane. The at least one semifluorinated alkane may also not have been subjected to a sterilisation process. The process may comprise mixing lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane to form a suspension, preferably wherein the at least one semifluorinated alkane consists of F6H8, and then sterilising the suspension (for example by gamma irradiation), thereby forming a suspension consisting essentially of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilisedsemifluorinated alkane. Following sterilisation of the suspension, the suspension may then be subjected to ball milling, as described below. All of the properties of the process and the composition described herein in the context of a process comprising mixing sterilised lifitegrast or a pharmaceutically acceptable salt thereof with at least one sterilised semifluorinated alkane (e.g. the amounts of the ingredients in the composition, the nature of the semifluorinated alkane, etc) apply equally to the processof mixing the lifitegrast or a pharmaceutically acceptable salt thereof with at least one semifluorinated alkane and then sterilising the suspension.Ball milling

[0076] Preferably, the process comprises ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof. Advantageously, the sterilised lifitegrast or a pharmaceutically acceptable salt thereof can be ball milled whilst suspended in the at least one sterilised semifluorinated alkane (i.e., there is no need for an alternative or additional liquid medium to effectively mill the lifitegrast particles), which simplifies the manufacturing process.

[0077] In order to improve the efficiency of the ball milling step, the process may comprise micronising the lifitegrast or a pharmaceutically acceptable salt thereof to reduce its particle size before it is mixed with the at least one semifluorinated alkane. Preferably, the process comprises micronising the lifitegrast or a pharmaceutically acceptable salt thereof before it is sterilised. The use of lifitegrast or a pharmaceutically acceptable salt thereof with a smaller particle diameter, for example a D90 particle diameter of about 10 pm or less, improves the efficiency of the ball milling step, although lifitegrast or a pharmaceutically acceptable salt thereof with a larger D90 particle diameter can be used, as discussed below.

[0078] It has been found that certain concentrations of lifitegrast in the suspension are particularly suitable for ball milling. At lifitegrast concentrations of around 20% (w / w) or above, the suspension forms a paste and the viscosity is too high for the particles to be milled efficiently. At lower concentrations of around 15% (w / w) or below, especially around 10% (w / w), the viscosity is acceptable for ball milling. Moreover, after milling, it is impractical to increase the concentration of lifitegrast particles because semifluorinated alkanes are not volatile and it is therefore difficult to remove semifluorinated alkane after it has been mixed with the lifitegrast particles. A concentration of at least 2% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis is preferred for the efficacy of the ophthalmic composition. Suspensions having a lifitegrast concentration of above 2% (w / w) have the additional advantage of being stable (i.e., little or no sedimentation is observed during prolonged storage) at suitable particle diameters.

[0079] The suspension of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and the at least one sterilised semifluorinated alkane that is subjected to ball milling may comprise from about 1% (w / w) to about 25% (w / w) of the sterilisedlifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis. However, for the reasons discussed above, the suspension that is subjected to ball milling preferably comprises from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof, more preferably from about 2% (w / w) to about 12% (w / w), even more preferably about 8% (w / w) to about 12% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof, and most preferably about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis.

[0080] The suspension that is subjected to ball milling may comprise from about 75% (w / w) to about 99% (w / w) of the at least one sterilised semifluorinated alkane, preferably from about 85% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane, more preferably from about 88% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane, even more preferably from about 88% (w / w) to about 92% (w / w) of the at least one sterilised semifluorinated alkane, and most preferably about 90% (w / w) of the at least one sterilised semifluorinated alkane.

[0081] The suspension that is subjected to ball milling preferably consists essentially of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane. Therefore, the suspension that is subjected to ball milling may consist essentially of (a) from about 1% (w / w) to about 25% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 75% (w / w) to about 99% (w / w) of the at least one sterilised semifluorinated alkane. Preferably, the suspension that is subjected to ball milling consists essentially of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 85% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane. More preferably, the suspension that is subjected to ball milling consists essentially of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) about 90% (w / w) of the at least one sterilised semifluorinated alkane.

[0082] In a preferred example, the suspension that is subjected to ball milling consists essentially of lifitegrast or a pharmaceutically acceptable salt thereof and at least one semifluorinated alkane. Therefore, the suspension that is subjected to ball milling may consist of (a) from about 1% (w / w) to about 25% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 75% (w / w) to about 99% (w / w) of the at least one sterilised semifluorinated alkane.Preferably, the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 85% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane. More preferably, the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) about 90% (w / w) of the at least one sterilised semifluorinated alkane.

[0083] In a more preferred example, the suspension that is subjected to ball milling consists essentially of lifitegrast or a pharmaceutically acceptable salt thereof and perfluorohexyloctane. Therefore, the suspension that is subjected to ball milling may consist of (a) from about 1% (w / w) to about 25% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 75% (w / w) to about 99% (w / w) of the sterilised perfluorohexyloctane. Preferably, the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) from about 85% (w / w) to about 98% (w / w) of the sterilised perfluorohexyloctane. More preferably, the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) about 90% (w / w) of the sterilised perfluorohexyloctane.

[0084] The ball milling step may comprise milling the particles of lifitegrast or a pharmaceutically acceptable salt thereof in a ball mill comprising balls having a diameter from about 0.05 mm to about 5 mm, preferably from about 0.1 mm to about 3 mm, more preferably from about 0.2 to about 1 mm, for example about 0.4 mm. Ball diameter is a standard form of sizing for balls used in ball mills. The ball mill may comprise balls made from alumina, zirconia, silicon nitride, or tungsten carbide, preferably zirconia.

[0085] Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 10 pm or less, for example from about 3 pm to about 10 pm. This prevents a sensation of grittiness in the eye. More preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 7 pm or less, for example from about 3 pm to about 7 pm. At a D90 particle diameter of about 7 pm or less, the delivery of lifitegrast to the target site is not limited by its dissolution rate, leading to improved drug delivery.

[0086] The lifitegrast or a pharmaceutically acceptable salt thereof may have a D50 particle diameter after ball milling of about 7 pm or less, for example from about 0.2 pmto about 7 pm, for example from about 0.5 pm to about 7 pm. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter after ball milling of about 4 pm or less, for example from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm. A Dso particle diameter of about 4 pm or less improves the stability of the suspension since less settling is observed during storage, as shown in the examples herein. The lifitegrast or a pharmaceutically acceptable salt thereof may have a Dso particle diameter after ball milling of from about 0.2 pm to about 1 pm, for example a Dso particle diameter of about 0.4 pm. Without being bound by theory, it is believed that smaller particle size may further enhance penetration through the ocular surface which may in turn enhance efficacy. It will naturally be understood that a reduction in Dso particle diameter will typically be accompanied by an associated reduction in D90 particle diameter.

[0087] The lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter after ball milling of about 10 pm or less, and a Dso particle diameter after ball milling of about 7 pm or less. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter after ball milling of about 7 pm or less, and a Dso particle diameter after ball milling of about 4 pm or less, for example, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter after ball milling of from about 3 pm to about 7 pm, and a Dso particle diameter after ball milling of from about 0.2 pm to about 4 pm, for example from about 0.5 pm to about 4 pm.

[0088] The D90 and Dso particle diameters before ball milling will be greater than the particle diameters after ball milling. The ball milling may reduce the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof, such as the D90 particle diameter and / or the Dso particle diameter, by at least about 10%, for example from about 10% to about 95% and preferably from about 25% to about 90%. The ball milling may reduce both the D90 particle diameter and the Dso particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least about 10%, for example from about 10% to about 95% and preferably from about 25% to about 90%.

[0089] When the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 10 pm or less, the D90 particle diameter before ball milling is typically at least about 11 pm, for example from about 11 pm to about 25 pm. When the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 7 pm or less, the D90 particle diameter before ball milling is typically at least about 8 pm, for example from about 8 pm to about 25 pm or from about 8 pm to about 12 pm.

[0090] When the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter after ball milling of about 7 pm or less, the Dso particle diameter before ball milling is typically at least about 8 pm, for example from about 8 pm to about 12 pm. When the lifitegrast or a pharmaceutically acceptable salt thereof has a Dso particle diameter after ball milling of about 4 pm or less, the Dso particle diameter before ball milling is typically at least about 5 pm, for example from about 5 pm to about 12 pm or from about 5 pm to about 10 pm.

[0091] Thus, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter before ball milling of from about 11 pm to about 25 pm, and a Dso particle diameter before ball milling of from about 8 pm to about 12 pm. Preferably, the lifitegrast or a pharmaceutically acceptable salt thereof may have a D90 particle diameter before ball milling of from about 8 pm to about 12 pm, and a Dso particle diameter before ball milling of from about 5 pm to about 10 pm.

[0092] Ball milling a suspension containing a higher concentration of lifitegrast improves the efficiency of the ball milling step and helps to achieve the desired particle diameter more quickly (providing the concentration of lifitegrast is not so high as to cause the cause the suspension to be too viscous, as explained above). After milling, the suspension may be diluted to obtain the desired concentration of lifitegrast or a pharmaceutically acceptable salt thereof in the final suspension. Thus, the process preferably comprises adding a second portion of at least one sterilised semifluorinated alkane to the suspension after the suspension has been subjected to ball milling. The at least one semifluorinated alkane added after milling can be the same as or different to the at least one semifluorinated alkane present in the suspension that is ball milled. Preferably, the at least one semifluorinated alkane added after milling is the same as the at least one semifluorinated alkane present in the suspension that is ball milled. More preferably, the at least one semifluorinated alkane present in the suspension that is ball milled consists of perfluorohexyloctane, and the at least one semifluorinated alkane added after milling also consists of perfluorohexyloctane.Filling into a container closure system

[0093] The process may comprise filling the suspension into a container closure system. The container closure system may comprise a bottle or a vial. The container closure systems may be multi-dose container closure systems. The container closure systems may comprise or consist essentially of polypropylene.Ophthalmic compositions

[0094] The invention also provides ophthalmic compositions in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and(b) at least one semifluorinated alkane, obtained by the process described herein. Preferably, the ophthalmic composition is in the form of a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane. More preferably, the ophthalmic composition is in the form of a suspension consisting essentially of (a) from about 2% (w / w) to about 6% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane, e.g. consisting of (a) from about 2% (w / w) to about 6% (w / w) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.

[0095] The ophthalmic composition is in the form of a liquid suspension. The lifitegrast or a pharmaceutically acceptable salt thereof is present as particles suspended in the semifluorinated alkane liquid, since lifitegrast is insoluble in semifluorinated alkanes.

[0096] The ophthalmic composition is typically a stable liquid composition, preferably a stable non-aqueous liquid composition.

[0097] The ophthalmic composition is typically a sterile liquid composition, preferably a sterile non-aqueous liquid composition.

[0098] Preferably, the ophthalmic composition is substantially free of pharmaceutically acceptable excipients, more preferably free of pharmaceutically acceptable excipients.

[0099] Preferably, the ophthalmic composition is substantially free of medium chain triglycerides and substantially free of semifluorinated alkyl alcohols. More preferably, the ophthalmic composition is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.

[0100] Preferably, the ophthalmic composition is substantially free of antioxidants and / or substantially free of preservatives (save for semifluorinated alkanes, considering these as preservatives). Further preferably, the ophthalmic composition is substantially free of both antioxidants and preservatives, more preferably free of both antioxidants and preservatives.

[0101] Preferably, the ophthalmic composition is substantially free of water, more preferably free of water.Methods for treatment

[0102] Further disclosed herein are methods for the treatment and / or temporary prevention of at least one ocular disorder, preferably dry eye disease, comprising administering to a patient in need thereof an effective amount of an ophthalmic composition obtained by the process described above for manufacturing anophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane.

[0103] Similarly, provided are: ophthalmic compositions obtained by the process described above, for use in a method for the treatment or temporary prevention of at least one ocular disorder.

[0104] Further provided is (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane for use in the manufacture of a medicament for the treatment or temporary prevention of at least one ocular disorder, preferably dry eye disease, wherein the medicament is an ophthalmic composition obtained by the process described above.

[0105] The ophthalmic composition produced by the process of the invention may be administered twice daily in each eye. This represents a reduced dosing frequency compared to an ophthalmic composition where perfluorohexyloctane is the sole active ingredient (Miebo™), which is typically administered four times daily.

[0106] The ophthalmic composition may be administered for at least 4 days, preferably for at least 10 days from the same container closure system. Due to the preservative effect of the semifluorinated alkane and the resulting stability of the ophthalmic composition, the composition can be provided in a multi-dose container closure system without the addition of potentially irritating preservatives or antioxidants. This is more convenient to the user than a single dose unit and generates less packaging waste.

[0107] Preferably, the ophthalmic composition is administered from the same container closure system twice daily in each eye for at least 4 days, more preferably for at least 10 days.

[0108] The at least one ocular disorder may include, but is not limited to, dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosacea presbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, styes, eye inflammation, eye discomfort or pain, itching of the eye, inflammatory dry eye, redness of the eye, watery eye, stinging or burning of the eye, gritty sensation of the eye, eye sensitivity to light, blurred vision, more frequent blinking, pressure behind the eye, eyelids that are greasy, crusty, itchy, swollen or sticking, and the like.

[0109] The at least one ocular disorder may be chosen from dry eye disease, dry eye, meibomian gland dysfunction, adult chlamydial ophthalmia, ocular rosaceapresbyopia, recalcitrant recurrent corneal erosions, ocular cicatricial pemphigoid, Sjogren’s syndrome (SS), non-SS keratoconjunctivitis sicca (KCS), conjunctivitis, allergic conjunctivitis, endophthalmitis, keratitis, uveitis, or any combination thereof.

[0110] The at least one ocular disorder may be chosen from conjunctivitis, keratitis, dry eye disease, or any combination thereof.

[0111] Preferably, the at least one ocular disorder is dry eye disease. The ophthalmic composition is particularly suitable for the treatment of dry eye disease and in particular for the treatment of mixed-type dry eye disease where the patient suffers from both aqueous deficient dry eye disease and evaporative dry eye disease, due to the presence of both lifitegrast and at least one semifluorinated alkane.

[0112] Therefore, the dry eye disease may be aqueous deficient dry eye disease. The dry eye disease may be evaporative dry eye disease. The suspension is particularly useful for treating patients wherein the dry eye disease is both aqueous deficient dry eye disease and evaporative dry eye disease.

[0113] The dry eye disease may have hyperosmolarity as a cause and / or as a symptom. The dry eye disease may have tear film instability as a cause and / or as a symptom. The dry eye disease may have both hyperosmolarity and tear film instability as a cause and / or as a symptom.

[0114] The examples support that ophthalmic compositions containing at least about 2% (w / w) lifitegrast will have good clinical efficacy against dry eye disease and will result in comparable or greater exposure of lifitegrast in the bulbar conjunctiva and cornea than a comparative aqueous solution. Thus, preferably, the method of treatment and / or temporary prevention of at least one ocular disorder, especially dry eye disease, comprises administering to a patient in need thereof an effective amount of an ophthalmic composition obtained by the process described above, wherein the lifitegrast or a pharmaceutically acceptable salt thereof is included in the composition at a concentration from about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), on a free acid basis. More preferably, the composition administered in the method consists essentially of: (a) about 2% (w / w) to about 6% (w / w), for example from about 2.5% (w / w) to about 5% (w / w), lifitegrast or a pharmaceutically acceptable salt thereof on a free acid basis and (b) perfluorohexyloctane (F6H8).BRIEF DESCRIPTION OF DRAWINGS

[0115] Figure 1 shows cumulative lifitegrast concentrations (pg / g) in EpiCorneal™ tissue after 4 hours.

[0116] Figure 2 shows the concentration (ng / g) of lifitegrast measured in cornea over time (0-8 hours).

[0117] Figure 3 shows a block diagram of an exemplary manufacturing process.EXAMPLESExample 1: Manufacturing process

[0118] An exemplary process for manufacturing a suspension of lifitegrast particles in perfluorohexyloctane (F6H8) is shown in Figure 3 and described in detail below. The F6H8 used in these examples consists essentially of 1 -perfluorohexyloctane and less than 0.5% (w / w) of 2-perfluorohexyloctane.1. Lifitegrast free acid is micronised using a jet mill to obtain a suitable particle diameter for ball milling (e.g., a D90 particle diameter of from about 8 pm to about 12 pm and a D50 particle diameter of from about 5 pm to about 10 pm).2. The micronised lifitegrast is sterilised by gamma irradiation using a radiation dose of 17.5 - 36.9 kGy.3. A first portion of the F6H8 liquid is filtered through a 0.2 pm sterilising filter and transferred into a sterilised mixing tank.4. The sterilised lifitegrast is added to the sterilized F6H8 liquid under aseptic conditions and mixed to prepare a suspension of 10% w / w lifitegrast in 90% w / w F6H8.5. The suspension is ball-milled using a validated Fryma-Koruma CoBall Mill MS18 with 0.4 mm zirconium oxide (ZrC ) beads to reduce the particle diameter of the lifitegrast.6. Once a suitable particle diameter has been obtained (e.g., a D90 particle diameter of 7 pm or less and a D50 particle diameter of about 4 pm or less), a second portion of the F6H8 liquid is filtered through a 0.2 pm sterilising filter and added to dilute the suspension that was subjected to ball milling to form a suspension of either (i) 5% w / w lifitegrast in 95% w / w F6H8 or (ii) 2.5% w / w lifitegrast in 97.5% w / w F6H8.7. The suspension is mixed.8. The final suspension is filled into a sterilised container closure system, such as container closure system comprising a bottle or vial.

[0119] This exemplary process provides a suspension with a high sedimentation volume (about 0.8 or more) and slow sedimentation velocity (about 1 mm / hr or less),resulting in good dispersibility and stability. Moreover, the small final particle diameter of lifitegrast means that the delivery of lifitegrast to the target site is not limited by its dissolution rate, leading to improved drug delivery.

[0120] A person skilled in the art would appreciate that each of the steps of the exemplary process described above may be modified or replaced within reason, for example, lifitegrast or F6H8 may be sterilised by an alternative method selected from sterile filtration, dry heat sterilization, gamma irradiation, or gas sterilisation (e.g. using ethylene oxide).Example 2: Gamma irradiated lifitegrast

[0121] Three samples of lifitegrast free acid, each having a bioburden of < 10 CFU / g, were sterilised using gamma irradiation at doses of 17.0 kGy, 22.1 kGy, and 36.9 kGy, respectively.

[0122] The sterilised samples and a control of unsterilised lifitegrast free acid were analysed using high performance liquid chromatography (HPLC). The relative peak area values for lifitegrast and any impurities were as follows:% Area (HPLC)Gamma Control Low Med High IrradiationDose (0 kGy) (17.0 kGy) (22.1 kGy) (36.9 kGy) Lifitegrast 99.8 98.3 97.82 96.94Total impurities 0.2 1.70 2.18 3.06

[0123] This data shows that the level of impurities present in gamma-sterilised lifitegrast is low. At the high radiation dose of 36.9 kGy, the total level of impurities is about 3% of the total composition. The safety of impurities generated during the gamma sterilisation was verified by in silico assessment.Example 3: Ball milling study

[0124] In the following examples, the particle size distribution was determined using a Horiba LA-960 particle analyser equipped with a Horiba MiniFlow circulation system, using the LA-960 for Windows V8.40 software and a Mie theory scattering model with a real and imaginary refractive index of 1.643 and 0.1 respectively. Before the measurement was taken, a dispersant of 0.1 % (w / w) sorbitan monooleate (Span® 80) in heptane was filtered through a 0.2 pm filter and added to the suspension of lifitegrast and F6H8 to give a mixture consisting of about 1% (w / w) suspension and about 99% (w / w) dispersant.

[0125] To investigate suitable ball milling conditions, slurries of lifitegrast particles in perfluorohexyloctane (F6H8) were ball milled at different mill speeds in a Fryma-Koruma CoBall Mill MS18 with 0.4 mm zirconium oxide (ZrC ) balls.Small scale studyBatch no. 1 2 3 4 Batch size (kg) 4 4 4 4 Concentration of lifitegrast (% w / w) 20 10 10 10 Number of passes through the mill 1 1 1 1Mill speed (m / s) 14 8 11 14 Pump speed (rpm) 6 30 15 6 Dio particle diameter (pm) 1.1 2.4 1.7 1.2 Dso particle diameter (pm) 1.8 4.4 3.6 2.5D90 particle diameter (pm) 3.3 7.4 6.9 6.0

[0126] At 20% (w / w) lifitegrast (batch 1), milling is feasible, but a paste forms that reduces the milling efficiency and makes the composition more difficult to handle. At 10% (w / w) lifitegrast, the composition has improved flowability. The particle size distribution improves with higher mill speed from batches 2 to 4. Lower particle size diameters are desirable to improve delivery of lifitegrast to the eye and to ensure that the delivery of lifitegrast is not limited by its dissolution rate.Clinical trial material (CTM) scale studyBatch no. 5 6 7 Batch size (kg) 25 25 25 Concentration of lifitegrast (% w / w) 10 10 10 Number of passes through the mill 1 2 1 Mill speed (m / s) 14 14 14 Pump speed (rpm) 6 6 30D10 particle diameter (pm) 1.0 1.0 2.3 Dso particle diameter (pm) 2.1 1.7 4.4D90 particle diameter (pm) 4.9 3.0 7.9

[0127] The best particle size distribution was obtained with batch 6, but the additional pass through the ball mill adds complexity to the manufacturing process. The faster pump speed for batch 7 resulted in a less favourable particle size distribution. The milling conditions for batch 5 result in desirable particle diameters and reduced manufacturing complexity and are therefore preferred.Example 4: Particle size and sedimentation study

[0128] This study investigated the sedimentation volume of different Lifitegrast suspensions with different particle sizes and concentrations to assess the influence of milling time and dilution on stability.

[0129] Three bulk suspensions of lifitegrast free acid at a concentration of approximately 7.5% (w / w) in perfluorohexyloctane (F6H8) were prepared as Suspensions A to C.

[0130] Suspension A was ball milled for 48 hours in a Fryma-Koruma CoBall Mill MS18 with 0.4 mm zirconium oxide (ZrO2) balls. Suspension B was milled under the same conditions for 2 hours. Suspension C was not milled at all.

[0131] To evaluate the impact of concentration on sedimentation behaviour, each suspension was divided into five batches, which were diluted with F6H8 to obtain five different concentrations. The suspensions were then transferred into glass vials and stored undisturbed under ambient conditions for 48 hours, allowing for natural sedimentation. The sedimentation volume (F) was measured for each of the 15 suspensions to assess physical stability. The sedimentation volume was calculated as follows:Volume of settled sediment (l^) Sedimentation volume (F) = — - - - - - — - - ; - TTTT-Total volume of the suspension (Ft) Ideally, the sedimentation volume is 1 or close to 1. This represents a stable suspension where there is minimal or no sedimentation. A sedimentation volume of less than 0.09 represents an unacceptably unstable suspension.

[0132] To assess the impact of particle size distribution (PSD) on sedimentation behavior, the median particle diameter (Dso) of each suspension (A, B, and C) was measured using a Horiba LA-960 particle size analyzer. The table below summarises the concentration, Dso particle diameter, and sedimentation volume for all suspensions.Dso particle Concentration of Sedimentation Suspensiondiameter (pm) lifitegrast (% w / w) volume (F) A-1 0.923 7.25 1.000A-2 0.923 3.63 1.000A-3 0.923 1.81 0.938A-4 0.923 0.91 0.500A-5 0.923 0.45 0.406B-1 3.943 7.50 1.000B-2 3.943 3.75 1.000B-3 3.943 1.88 0.938B-4 3.943 0.94 0.688B-5 3.943 0.47 0.400C-1 6.329 7.50 1.000C-2 6.329 3.75 1.000C-3 6.329 1.88 0.500C-4 6.329 0.94 0.250C-5 6.329 0.47 0.133

[0133] All suspensions having a lifitegrast concentration of greater than about 3.6-3.75% (w / w) exhibited ideal suspension behaviour with a sedimentation volume of 1.

[0134] Suspension A (48-hour milling) had the smallest lifitegrast Dso particle diameter of 0.923 pm, and Suspension B (2-hour milling) had an intermediate lifitegrast Dso particle diameter of 3.943 pm. For lifitegrast concentrations of less than 2% (w / w), Suspensions A and B possessed similar sedimentation volumes at similar lifitegrast concentrations. However, both Suspensions A and B exhibited markedly higher sedimentation volumes and therefore greater stability than the corresponding concentrations for Suspension C. This shows that milling to reduce particle size, in particular to obtain a Dso particle diameter of about 4 pm or less, results in an improvement in suspension stability. However, the similar sedimentation behaviour of Suspensions A and B implies that continued milling to reduce the Dso particle diameter beyond about 4 pm is of limited further benefit.

[0135] Suspension C (unmilled) had the largest lifitegrast Dso particle diameter of 6.329 pm. For lifitegrast concentrations of less than 2% (w / w), Suspension C possessed lower sedimentation volumes and therefore lower stability than the corresponding concentrations for Suspensions A and B. Nevertheless, Suspension C still possessed good stability, especially at a concentration of about 2% (w / w) and above, and more especially at 3.75% (w / w) and above.

[0136] This study demonstrates that the concentration of suspended lifitegrast particles significantly affects sedimentation volume and therefore the stability of the suspension. It also shows that reducing particle size through milling improves suspension stability by increasing sedimentation volume. A suspension with higher stability is advantageous because it results in a more uniform dispersion of lifitegrast particles, which improves the consistency of the concentration of lifitegrast particles that is delivered to the eye with each drop of the ophthalmic composition.

[0137] It is shown in the examples of PCT / EP2024 / 082568 that stable, sterile suspensions of lifitegrast free acid and perfluorohexyloctane can be obtained without the addition of a preservative or antioxidant. It is further shown that these suspensionsachieve similar ocular exposure as aqueous I ifitegrast solutions at only one third of the dose.Example 5: F6H8 preservative activity

[0138] The antimicrobial properties of F6H8 were evaluated according to the Ph. Eur. 5.1.3 method. Results were as follows:Organism Time Count Log reduction Inoculum 2 x 105- 0 hour 16 4.1S. aureus 6 hours 0 5.324 hours 0 5.328 days 0 5.3Inoculum 8 x 105- 0 hour 5 x 1041.2P. aeruginosa 6 hours 4 x 1023.324 hours 8 5.028 days 0 5.9Inoculum 2 x 105- 0 hour 2 x 1041.0E. coli 6 hours 0 5.324 hours 0 5.328 days 0 5.3Inoculum 9 x 105- 0 hour 5 x 1032.3C. albicans7 days 0 6.028 days 0 6.0Inoculum 7 x 105- 0 hour 8 x 1040.9A. brasiliensis7 days 1 x 1032.828 days 2 x 1032.5

[0139] F6H8 meets the acceptance criteria for this assay, namely that (a) the concentrations of viable bacteria show not less than a 2 log reduction from the initial calculated count at 6 hours, not less than a 3 log reduction at 24 hours, and no recovery at 28 days and (b) the concentrations of yeasts and molds show not less than a 2 log reduction from the initial calculated count at 7 days, with no increase at 28 days. Thus F6H8 meets the antimicrobial effectiveness requirements without the need for extrinsic preservative.

[0140] This result can be explained by the lack of water activity in the F6H8 liquid. Addition of solid lifitegrast introduces no water activity and so this mixture also will not support microbial growth.Example 6: Suspensions

[0141] Lifitegrast free acid was added to F6H8 in various proportions, including (w / w) 0.25%, 1%, 2%, 2.5%, 4%, 5%, and 10%. The lifitegrast is in soluble in F6H8 and forms a suspension. When left standing the lifitegrast settles to form a sediment.

[0142] Lifitegrast is stable in the suspensions. During storage at 40°C levels of lifitegrast in a 4% suspension ( / .e. 96% (w / w) F6H8, 4% (w / w) lifitegrast) did not change:Time (months) 0 1 3Lifitegrast (%) 99.87 99.87 99.89

[0143] Similar results were seen in a 2% suspension. No significant impurities were seen when stored at 25°C for 3 months. A minor impurity increase was seen after 3 months at 40°C, but it was insignificant. Thus lifitegrast and F6H8 are chemically compatible. The same compatibility can be expected with other semifluorinated alkanes as they do not include any additional reactive groups.

[0144] Lifitegrast / F6H8 suspensions were supplemented with a-tocopherol or tocopheryl acetate as antioxidants (e.g. 2% lifitegrast, 93% F6H8, 5% tocopheryl acetate). After storage for 1 month at 40°C levels of lifitegrast-derived impurities showed no significant differences with or without the antioxidants (e.g. for a 2% emulsion with 5% tocopheryl acetate the level of lifitegrast was 99.92% at time zero and still after 3 months at 40°C). Oxidation-derived degradation products were not detected with or without antioxidant. Lifitegrast and F6H8 are therefore compatible, without needing addition of any antioxidant.

[0145] Suspensions with 2% or 5% lifitegrast were subjected to centrifugation for 1 hour at 500, 750 or 1000 rpm to accelerate settling of the lifitegrast powder, and the ease and efficiency of redispersibility were evaluated by shaking the settled product by hand (conditions to mimic patient use). After 500 rpm centrifugation the powder could be resuspensed by one gentle inversion. After 750 or 1000 rpm centrifugation resuspension required several gentle inversions or shaking by hand 2 or 3 times. Thus the suspensions show redispersibility which is acceptable for patient use.

[0146] Suspensions were filled into polypropylene bottles with a dropper outlet and droplets were weighed. Droplets of F6H8 alone had a mass of 15.91 mg with astandard deviation of 0.55 mg, with a volume of 11.35 pL. Droplets of the 5% I ifitegrast suspension weighed 15.93 mg with a standard deviation of 0.43 mg, with a volume of 11.85 pL. Droplets of the suspensions thus show acceptable dose uniformity within a bottle, and lifitegrast does not interfere with the ability of F6H8 to form droplets.

[0147] Droplets of the F6H8 suspension are ~3x smaller than the aqueous droplets of Xiidra™ (5% lifitegrast solution), and so the amount of lifitegrast delivered by a single droplet of 5% suspension is lower than the amount delivered by a single Xiidra™ droplet.Example 7: Ocular irritation assessment

[0148] The ocular tolerability of lifitegrast free acid / F6H8 suspensions (5%) were assessed, including evaluation of sting / burn reactions relative to the marketed lifitegrast solution (Xiidra™) and the marketed F6H8 product (Miebo™). NZW rabbits (3 per group) received topical ocular doses QID for 5 Days (40 pL / dose = 160 pL / eye / day). Ocular irritation was assessed by (a) macroscopic examination (Draize scoring) after the fourth daily dose and, if irritation was noted, again in the following morning and (b) microscopic examination by slit lamp and indirect ophthalmoscopy at days 0 & 5. Sting / burn assessments were taken after the second and fourth daily dose, recording the cumulative duration of blinking / squinting and also noting other indicators (e.g., rubbing).

[0149] The suspensions were well tolerated with no toxicologically significant findings after 5 days of dosing.

[0150] The maximum weighted score for irritation in any animal was scored as 4 out of a maximum of 110. Suspensions were well tolerated and any negative effects (redness, discharge, conjunctival congestion) were short-lived and did not increase in seventy over the duration of the study.Example 8: Epicorneal tissue model

[0151] The EpiCorneal 3D human tissue model (MatTek) provides a predictive non-animal model for assessing ophthalmic drug delivery. This model was used to assess the effect of F6H8 on lifitegrast permeability and the dose-dependence of permeability characteristics.

[0152] Seven formulations were tested: four suspensions (0.25%, 1%, 2.5% and 5%), a second 1% suspension, and two aqueous solutions (1% and 5%). 12 pL volumes were administered to the model and assessed for permeability (collecting 200 pL samples from the receiver at 15, 30, 60, 120, 180 and 240 minutes to measurepenetrated lifitegrast concentration) and for lifitegrast concentration in EpiComeal tissue after 240 minutes.

[0153] Suspensions had lower lifitegrast permeability than solutions but higher tissue accumulation. A dose-dependent increase in tissue accumulation was observed from 0.25% to 2.5% with the suspensions. Figure 1 shows cumulative lifitegrast concentrations in EpiCorneal tissue after 4 hours, indicating that the two 1% suspensions provided about the same performance as a 5% aqueous solution, and the 5% suspension provided higher tissue accumulation than the 5% solution. Slower permeation into the receiver using the suspensions might be explained by the need for the solid lifitegrast to dissolve before it can permeate.Example 9: Ocular pharmacokinetic study

[0154] An in vivo pharmacokinetic study was used to evaluate dose-dependent ocular bioavailability of lifitegrast free acid / F6H8 suspensions in dutch belted rabbits. Four suspensions were tested (10%, 5%, and 2x 1 %) and compared to a 5% aqueous solution:

[0155] Ingredient Cone. (%w / w)5% sol" 1 % susp" 5% susp" 10% susp" Lifitegrast 5 1 5 10 Perfluorohexyloctane - 99 95 90 Sodium chloride 0.3 - - - Sodium thiosulfate 0.29 - - - Sodium phosphate - - - 0.35dibasicSodium hydroxide - - - 7.49(1 N) solutionPurified water q.s. - - -

[0156] The dosage volume per eye was 12 pL for the suspensions and 35 pL for the solution. Samples of cornea, bulbar conjunctiva, aqueous humor, anterior sclera, and palpebra conjunctiva were taken after 0.25, 1 , 3, and 8 hours. Corneal results are shown in Figure 2.

[0157] Dose-proportional ocular exposure of lifitegrast was seen with suspensions from 1-5%, with a higher than proportional increase in exposure at 10%.

[0158] Areas under the lifitegrast concentration-time curve from 0 to 8 hours (AUCo-8hr) were calculated with linear trapezoidal linear interpolation method using WinNonlin. Values were as follows, relative to the aqueous solution (100%):5% sol" 1 % susp" 1 % susp" 5% susp" 10% susp" Cornea 100 11 9 77 148 B.conj 100 36 28 212 642 P.conj 100 27 17 150 552Aq humor 100 14 13 55 309Sclera 100 13 15 60 195

[0159] The 5% suspension dose at 12 pL gave the most similar ocular exposure to 5% solution dosed at 35 pL. Thus the administered amount of lifitegrast can be reduced 3-fold while achieving the same ocular exposure.

[0160] Maximum observed concentration (Cmax) values were determined relative to the aqueous solution (100%):5% sol" 1% susp" 1% susp" 5% susp" 10% susp" Cornea 100 10 10 72 115 B.conj 100 36 68 216 706 P.conj 100 27 30 179 525Aq humor 100 14 18 115 688Sclera 100 21 35 132 177

[0161] The 5% suspension in F6H8 achieved an approximately two-fold increase in Cmax and AUCo-shr in the conjunctiva, despite the total dose of lifitegrast being about one third of the dose administered with the 5% aqueous solution (due to the difference in droplet size). Without being bound by theory, the conjunctiva is an important tissue in the pathology of dry eye disease because it is the site of mucin-secreting goblet cells, which are important for tear film quality and can be damaged by inflammation. Moreover, the conjunctiva is believed to be the primary site of immune cells on the ocular surface, which makes it a likely primary site of action for lifitegrast. Therefore, the increase in Cmax and AUCo-shr in the conjunctiva means that the total dose of lifitegrast can be lowered (e.g., by using a smaller drop of a similar dose-strength) while delivering more of the drug to the presumed primary site of action.Example 10: Human pharmacokinetic modelling data

[0162] A nonparametric superpositioning (NSP) method implemented in Pheonix WinNonlin software was used to model single dose pharmacokinetic data from rabbitsand to simulate steady state drug exposure at the human conjunctiva and cornea based on those data.

[0163] The model used the following lifitegrast concentration data in the bulbar conjunctiva and cornea of rabbits following administration of a single drop of 12 pL of a suspension of 5% (w / w) and 1% (w / w) lifitegrast in F6H8 or 35 pL of an aqueous solution of 5% (w / w) lifitegrast. The difference in drop size means that the delivered dose of lifitegrast from a single drop of the aqueous solution is more than double the dose of lifitegrast from a single drop of the suspension for the same concentration of lifitegrast. The data relating to 1% and 5% lifitegrast / F6H8 suspensions were used to simulate steady state drug exposure of 1%, 1.5%, 2%, 2.5% and 5% suspensions in humans dosed with a 12 pL drop BID for 3 days. The data relating to 5% lifitegrast aqueous solution were used to simulate steady state drug exposure of 0.1%, 1% and 5% aqueous solutions in humans dosed with a 35 pL drop BID for 3 days. The conversion involved multiplying the exposure in rabbits by 40% to convert the exposure values to expected exposure in humans.Lifitegrast concentrations in B. conjunctiva and cornea in rabbits following a single drop of 12 L of a suspension ora single drop of 35 pL of a solution Concentration (ng / g)Tissue Formulation0.25 1 h 3 h 8 h5% Solution 18300 7200* 19400 6690 B. Conj 1% Suspension 6100 2240* 6910 28205 % Suspension 41900 41900 24700 21800 5% Solution 7020 5130 4930 2240 Cornea 1 % Suspension 666.7 471.3 641.6 197.35 % Suspension 5040 3060 4280 1570 ‘Handled as outliers. The outliers were removed and imputed with extrapolated values based on first order elimination.

[0164] The model makes the following assumptions:• Each dose acts independently• There is no change in absorption between doses• There is no change in clearance between doses• Linear kinetics apply (dose proportionality)

[0165] The following results predict exposure in human bulbar conjunctiva at steady state:Formulation Cmax (ng / g) Ctau (ng / g) AUCtau (ng -h / g) 5% Suspension 10416 3840 755005% Solution 9321 1910 636832.5% Suspension 5208 1920 377502% Suspension 4179 1536 302081.5% Suspension 3134 1152 226561% Suspension 3547 969 260261% Solution 1864 382 12737Note: Cmax, Ctau and AUCtau of LIF in human B. conjunctiva were obtained in the simulated profile between 60 to 72 hours.

[0166] The following results predict exposure in human cornea at steady state: Formulation Cmax (ng / g) Ctau (ng / g) AUCtau (ng-h / g) 5% Suspension 2498 579 157225% Solution 3394 720 203652.5% Suspension 1249 290 78612% Suspension 1030 232 64891.5% Suspension 485 88 29931% Suspension 313 59 19951% Solution 679 144 4073Note: Cmax, Ctau and AUCtau of LIF in human cornea were obtained in the simulated profile between 60 to 72 hours.

[0167] Both 1% and 5% aqueous solutions of lifitegrast are known to have clinical efficacy, as reported in Semba et al. Am J Ophthalmol, 2012;153:1050-1060. Therefore, results relating to the suspension that show a comparable or higher exposure to lifitegrast than the results relating to the 1% and 5% aqueous solutions are also expected to be clinically efficacious.In the bulbar conjunctiva, which is believed to be a primary site of action of lifitegrast, the simulated results for the 5% suspension surprisingly predict greater exposure than for the 5% aqueous solution, and likewise, the simulated results for the 1-2.5% suspensions predict greater exposure than the 1% aqueous solution. This is even more surprising given the smaller drop size, and therefore smaller dose of lifitegrast, for the suspensions compared to the aqueous solutions. For the same reasons, it was also surprising that the simulated results for 2-2.5% suspensions predict greater exposure in the cornea, which is also an important site of action for lifitegrast, than for the 1% aqueous solution. This data therefore indicates that suspensions of lifitegrast in F6H8, and in particular suspensions containing at least about 2% (w / w) lifitegrast(e.g., suspensions comprising about 2% (w / w) to about 6% (w / w) lifitegrast), will have good clinical efficacy and result in comparable or greater exposure of lifitegrast in the bulbar conjunctiva and cornea than a higher dose of the aqueous solution at the same concentration.

[0168] It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.NUMBERED EMBODIMENTSA process for manufacturing an ophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, wherein the process comprises:(i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane; and(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension.A process for manufacturing an ophthalmic composition in the form of a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane, wherein the process comprises:(i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b sterilised perfluorohexyloctane; and (ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the sterilised perfluorohexyloctane, thereby forming a suspension.The process of numbered embodiment 1 or numbered embodiment 2, wherein the process comprises sterilising the lifitegrast or a pharmaceutically acceptable salt thereof.The process of numbered embodiment 3, wherein the process comprises sterilising the lifitegrast or a pharmaceutically acceptable salt thereof by sterile filtration, gamma irradiation, or ethylene oxide.The process of numbered embodiment 4, wherein the process comprises sterilising the lifitegrast or a pharmaceutically acceptable salt thereof by gamma irradiation, optionally wherein the radiation dose is from about 15 kGy to about 40 kGy.The process of any one of the preceding numbered embodiments, wherein the process comprises sterilising the at least one semifluorinated alkane, for example, sterilising perfluorohexyloctane.The process of numbered embodiment 6, wherein the process comprises sterilising the at least one semifluorinated alkane by sterile filtration, dry heat sterilisation, gamma irradiation, or gas sterilisation.The process of numbered embodiment 7, wherein the process comprises sterilising the at least one semifluorinated alkane by sterile filtration.The process of numbered embodiment 8, wherein the filter is selected from a 0.1 micron filter, 0.2 micron filter, and 0.22 micron filter, for example wherein the filter is a 0.2 micron filter.The process of numbered embodiment 8 or numbered embodiment 9, wherein the filter material is selected from nylon, polycarbonate, cellulose acetate, polyvinylidene (PVDF), and polyethersulfone (PES), for example wherein the filter material is polyvinylidene (PVDF) or polyethersulfone (PES).The process of any one of the preceding numbered embodiments, wherein the process comprises filling the suspension into a container closure system.The process of any one of the preceding numbered embodiments, wherein the process comprises ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof.The process of numbered embodiment 12, wherein the process comprises adding a second portion of the at least one sterilised semifluorinated alkane to the suspension after the suspension has been subjected to ball milling.The process of any one of the preceding numbered embodiments, wherein the process comprises:(i) providing, separately, (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane;(ii) sterilising the lifitegrast or a pharmaceutically acceptable salt thereof; (iii) sterilising the at least one semifluorinated alkane;(iv) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension;(v) ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof;(vi) adding a second portion of the at least one sterilised semifluorinated alkane to the suspension after the suspension has been subjected to ball milling; and(vii) filling the suspension into a container closure system.The process of any one of the preceding numbered embodiments, wherein the process comprises:(i) providing, separately, (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) perfluorohexyloctane;(ii) sterilising the lifitegrast or a pharmaceutically acceptable salt thereof; (iii) sterilising the perfluorohexyloctane;(iv) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the sterilised perfluorohexyloctane, thereby forming a suspension;(v) ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and sterilised perfluorohexyloctane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof;(vi) adding a second portion of sterilised perfluorohexyloctane to the suspension after the suspension has been subjected to ball milling; and (vii) filling the suspension into a container closure system.The process of any one of numbered embodiments 12-14, wherein the suspension that is subjected to ball milling consists essentially of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and the at least one sterilised semifluorinated alkane.The process of any one of numbered embodiments 12-14, wherein the suspension that is subjected to ball milling consists of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and the at least one sterilised semifluorinated alkane.The process of any one of numbered embodiments 12-15, wherein the suspension that is subjected to ball milling consists essentially of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and sterilised perfluorohexyloctane.The process of any one of numbered embodiments 12-15, wherein the suspension that is subjected to ball milling consists of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and sterilised perfluorohexyloctane. The process of any one of numbered embodiments 12-19, wherein the suspension that is subjected to ball milling comprises from about 1% (w / w) to about 25% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of numbered embodiments 12-20, wherein the suspension that is subjected to ball milling comprises from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable saltthereof, for example about 8% (w / w) to about 12% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling comprises from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof, for example about 8% (w / w) to about 12% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof, and sterilised perfluorohexyloctane.The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling comprises from about 75% (w / w) to about 99% (w / w) of the at least one sterilised semifluorinated alkane.The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling comprises from about 85% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane, for example about 90% (w / w) of the at least one sterilised semifluorinated alkane. The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling consists essentially of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane, for example wherein the suspension that is subjected to ball milling consists essentially of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of the at least one sterilised semifluorinated alkane.The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of the at least one sterilised semifluorinated alkane, for example wherein the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of the at least one sterilised semifluorinated alkane.The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling consists essentially of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of sterilised perfluorohexyloctane, for example wherein the suspension that is subjected to ball milling consists essentially of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of sterilised perfluorohexyloctane.The process of any one of numbered embodiments 12-21 , wherein the suspension that is subjected to ball milling consists of (a) from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 85% (w / w) to about 98% (w / w) of sterilised perfluorohexyloctane, for example wherein the suspension that is subjected to ball milling consists of (a) about 10% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) about 90% (w / w) of sterilised perfluorohexyloctane.The process of any one of the preceding numbered embodiments, wherein the process comprises micronising the lifitegrast or a pharmaceutically acceptable salt thereof before it is mixed with the at least one semifluorinated alkane, for example wherein the process comprises micronising the lifitegrast or a pharmaceutically acceptable salt thereof before it is sterilised.The process of any one of numbered embodiments 12-29, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 10 pm or less, for example from about 3 pm to about 10 pm. The process of numbered embodiment 30, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter before ball milling of at least about 11 pm, for example from about 11 pm to about 25 pm. The process of any one of numbered embodiments 12-29, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 7 pm or less, for example from about 3 pm to about 7 pm. The process of numbered embodiment 32, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter before ball milling of at least about 8 pm, for example from about 8 pm to about 12 pm. The process of any one of numbered embodiments 12-33, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 7 pm or less, for example from about 0.5 pm to about 7 pm. The process of numbered embodiment 34, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter before ball milling of at least about 8 pm, for example from about 8 pm to about 12 pm. The process of any one of numbered embodiments 12-33, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 4 pm or less, for example from about 0.5 pm to about 4 pm. The process of numbered embodiment 36, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter before ball milling of at least about 5 pm, for example from about 5 pm to about 10 pm.The process of any one of numbered embodiments 12-37, wherein the ball milling reduces the D90 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least 10%, for example from about 10% to about 95%.The process of any one of numbered embodiments 12-38, wherein the ball milling reduces the D50 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least 10%, for example from about 10% to about 95%.The process of any one of numbered embodiments 12-39, wherein the ball milling step comprises milling the particles of lifitegrast or a pharmaceutically acceptable salt thereof in a ball mill comprising balls having a diameter from about 0.05 mm to about 5 mm, for example from about 0.1 mm to about 3 mm, for example from about 0.2 to about 1 mm.The process of any one of numbered embodiments 12-40, wherein the ball mill comprises balls made from alumina, zirconia, silicon nitride, or tungsten carbide, for example wherein the balls are made from zirconia.The process of any one of the preceding numbered embodiments, wherein the process forms a suspension comprising from about 0.1% (w / w) to about 10% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 2% (w / w) to about 8% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 2% (w / w) to about 6% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 2.5% (w / w) to about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of the preceding numbered embodiments, wherein the process forms a suspension comprising about 2.5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of the preceding numbered embodiments, wherein the process forms a suspension comprising about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof.The process of any one of the numbered embodiments, wherein the process is a process for manufacturing a composition consisting of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane.The process of any one of the preceding numbered embodiments, wherein the process forms a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane.The process of any one of the numbered embodiments, wherein the process is a process for manufacturing a composition consisting of sterilised I ifitegrast or a pharmaceutically acceptable salt thereof and sterilised perfluorohexyloctane (F6H8).The process of any one of the preceding numbered embodiments, wherein the process forms a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane. The process of any one of the preceding numbered embodiments, wherein the process is for manufacturing a suspension consisting of (a) from about 2% (w / w) to about 8% (w / w), for example from about 2% (w / w) to about 6% (w / w) of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.The process of any one of the preceding numbered embodiments, wherein the process forms a suspension consisting essentially of (a) from about 2% (w / w) to about 8% (w / w), for example from about 2% (w / w) to about 6% (w / w) of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.The process of any one of the preceding numbered embodiments, wherein the process is for manufacturing a suspension consisting of (a) from about 2.5% (w / w) to about 5% (w / w) of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.The process of any one of the preceding numbered embodiments, wherein the process forms a suspension consisting essentially of (a) from about 2.5% (w / w) to about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.The process of any one of the preceding numbered embodiments, wherein the process is for manufacturing a suspension consisting of (a) about 2.5% (w / w) or about 5% (w / w) of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.The process of any one of the preceding numbered embodiments wherein the process forms an ophthalmic composition consisting essentially of: (a) about 2.5% (w / w) or about 5% (w / w) lifitegrast or a pharmaceutically acceptable salt thereof, and (b) perfluorohexyloctane (F6H8).The process of any one of numbered embodiments 1-49, wherein the process forms a suspension consisting essentially of (a) from about 2.5% (w / w) to about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof and (b) from about 95% (w / w) to about 97.5% (w / w) of at least one semifluorinated alkane. The process of any one of the preceding numbered embodiments, wherein the lifitegrast is in the form of lifitegrast free acid.The process of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane is chosen from F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof; optionally wherein the composition includes no more than two semifluorinated alkanes.The process of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane comprises at least one of perfluorohexyloctane (F6H8) or perfluorohexyldecane (F6H10).The process of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8).The process of any one of the preceding numbered embodiments, wherein the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8) and is substantially free of other semifluorinated alkanes.The process of any one of the preceding numbered embodiments wherein the process forms an ophthalmic composition consisting essentially of: (a) about 2.5% (w / w) or about 5% (w / w) I ifitegrast or a pharmaceutically acceptable salt thereof, and (b) perfluorohexyloctane (F6H8).The process of any one of the preceding numbered embodiments, wherein the process does not comprise adding a medium chain triglyceride and does not comprise adding a semifluorinated alkyl alcohol.The process of any one of the preceding numbered embodiments, wherein the process forms an ophthalmic composition that is free of medium chain triglycerides and free of semifluorinated alkyl alcohols.The process of any one of the preceding numbered embodiments, wherein the process does not comprise adding a preservative and does not comprise adding an antioxidant.The process of any one of the preceding numbered embodiments, wherein the process forms an ophthalmic composition that is at least one of (i) substantially free of an antioxidant and (ii) substantially free of a preservative, optionally wherein the composition is substantially free of an antioxidant and substantially free of a preservative.

Claims

CLAIMS1. A process for manufacturing an ophthalmic composition in the form of a suspension comprising (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane, wherein the process comprises:(i) providing, separately, (a) sterilised lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane; and(ii) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension.

2. The process of claim 1 , wherein the process comprises ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof.

3. The process of claim 2, wherein the process comprises adding a second portion of the at least one sterilised semifluorinated alkane to the suspension after the suspension has been subjected to ball milling.

4. The process of any one of the preceding claims, wherein the process comprises:(i) providing, separately, (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one semifluorinated alkane;(ii) sterilising the lifitegrast or a pharmaceutically acceptable salt thereof; (iii) sterilising the at least one semifluorinated alkane;(iv) mixing the sterilised lifitegrast or a pharmaceutically acceptable salt thereof with the at least one sterilised semifluorinated alkane, thereby forming a suspension;(v) ball milling the suspension of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane, thereby reducing the particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof;(vi) adding a second portion of the at least one sterilised semifluorinated alkane to the suspension after the suspension has been subjected to ball milling; and(vii) filling the suspension into a container closure system.

5. The process of any one of claims 2-4, wherein the suspension that is subjected to ball milling comprises from about 2% (w / w) to about 15% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof, for example about 8% (w / w) to about 12% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof.

6. The process of any one of claims 2-5, wherein the suspension that is subjected to ball milling consists of from about 2% (w / w) to about 15% (w / w) of the sterilised I ifitegrast or a pharmaceutically acceptable salt thereof, for example about 8% (w / w) to about 12% (w / w) of the sterilised lifitegrast or a pharmaceutically acceptable salt thereof, and sterilised perfluorohexyloctane.

7. The process of any one of claims 2-6, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 10 pm or less, for example from about 3 pm to about 10 pm.

8. The process of any one of claims 2-6, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D90 particle diameter after ball milling of about 7 pm or less, for example from about 3 pm to about 7 pm.

9. The process of any one of claims 2-8, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 7 pm or less, for example from about 0.5 pm to about 7 pm.

10. The process of any one of claims 2-8, wherein the lifitegrast or a pharmaceutically acceptable salt thereof has a D50 particle diameter after ball milling of about 4 pm or less, for example from about 0.5 pm to about 4 pm.

11. The process of any one of claims 2-10, wherein the ball milling reduces the D90 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least 10%, for example from about 10% to about 95%.

12. The process of any one of claims 2-11 , wherein the ball milling reduces the D50 particle diameter of the lifitegrast or a pharmaceutically acceptable salt thereof by at least 10%, for example from about 10% to about 95%.

13. The process of any one of the preceding claims, wherein the process forms a suspension comprising from about 0.1% (w / w) to about 10% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof.

14. The process of any one of the preceding claims, wherein the process forms a suspension comprising from about 2% (w / w) to about 8% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof, for example from about 2% (w / w) to about 6% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof.

15. The process of any one of the preceding claims, wherein the at least one semifluorinated alkane comprises perfluorohexyloctane (F6H8) and is substantially free of other semifluorinated alkanes.

16. The process of any one of the preceding claims, wherein the process is a process for manufacturing a composition consisting of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and at least one sterilised semifluorinated alkane.4817. The process of any one of the preceding claims, wherein the process forms a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) at least one sterilised semifluorinated alkane.

18. The process of any one of the preceding claims, wherein the process is a process for manufacturing a composition consisting of sterilised lifitegrast or a pharmaceutically acceptable salt thereof and sterilised perfluorohexyloctane (F6H8).

19. The process of any one of the preceding claims, wherein the process forms a suspension consisting essentially of (a) lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.

20. The process of any one of the preceding claims, wherein the process forms a suspension consisting essentially of (a) from about 2.5% (w / w) to about 5% (w / w) of lifitegrast or a pharmaceutically acceptable salt thereof and (b) sterilised perfluorohexyloctane.21.The process of any one of the preceding claims, wherein the lifitegrast is in the form of lifitegrast free acid.

22. The process of any one of the preceding claims, wherein the process does not comprise adding a medium chain triglyceride and does not comprise adding a semifluorinated alkyl alcohol.

23. The process of any one of the preceding claims, wherein the process does not comprise adding a preservative and does not comprise adding an antioxidant.49